Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07293715 · ClinicalTrials.gov registry record · Phase 4
Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)
A Phase 4 study, sponsored by Ohio State University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT07293715 is a Phase 4 study that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 44 participants.
The verdict
NCT07293715, a Phase 4 study, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
PRISM-TID is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with type 1 diabetes (T1D) using hybrid closed loop therapy (HCL) who are admitted for labor management. Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia compared with strict intrapartum glucose management.
Interventions
- DRUG Insulin
- DEVICE DEXCOM Continuous Glucose Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-02-25 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07293715
The ClinicalTrials.gov registry entry for NCT07293715 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin is the first listed.
NCT07293715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07293715 about?
NCT07293715 is a clinical study titled "Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)". PRISM-TID is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with type 1 diabetes (T1D) using hybrid closed loop therapy (HCL) who are ad...
What is the current status of trial NCT07293715?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2026-02-25. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07293715?
The interventions under investigation include: Insulin (DRUG), DEXCOM Continuous Glucose Monitor (DEVICE).
Who is sponsoring clinical trial NCT07293715?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.